Philip Morris $PM (-1,34 %)
sells Vectura to Molex at a loss.
PM bought Vectura, a manufacturer of inhalable drugs, in July 2021 for 1.2 billion US dollars. It has now been sold to Molex Asia Holdings for 245 Mln US dollars.
Personally, I was quite split on PM's investment in medical products. On the one hand, it is of course a great platform for future products, but on the other hand there is a high risk of lawsuits. Although initial progress has already been made, there have also been the first warning signs of potential lawsuits.
Here is an article about the problems with the Vectura products
